Boston Scientific Corp
BSX101.140USD
+2.219+2.24%
Close 04/24, 16:00（ET）Quotes delayed by 15 min
149.14BMarket Cap
80.48P/E TTM
More Details of Boston Scientific Corp Company
Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company's MedSurg segment includes Endoscopy, Urology, and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal conditions with less-invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia, prostate cancer, erectile dysfunction, and incontinence. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. The Cardiology includes interventional cardiology therapies, watchman, cardiac rhythm management, and electrophysiology.
Company Info
Company codeBSX
Company nameBoston Scientific Corp
IPO dateMay 19, 1992
Founded at1979
CEOMr. Michael F. (Mike) Mahoney
Number of employees53000
Security typeOrdinary Share
Fiscal year-endMay 19
Address300 Boston Scientific Way
CityMARLBOROUGH
Stock exchangeNYSE Consolidated
CountryUnited States of America
Postal code01752-1234
Phone15086834000
Websitehttps://www.bostonscientific.com/en-US/Home.html
Company codeBSX
IPO dateMay 19, 1992
Founded at1979
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Michael F. (Mike) Mahoney
Mr. Michael F. (Mike) Mahoney
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
1.87M
-3.05%
Mr. Charles J. Dockendorff, CPA
Mr. Charles J. Dockendorff, CPA
Independent Director
Independent Director
62.90K
--
Mr. John E. Sununu
Mr. John E. Sununu
Independent Director
Independent Director
52.64K
--
Mr. Vance R. Brown
Mr. Vance R. Brown
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
36.19K
-11.77%
Ms. Ellen M. Zane
Ms. Ellen M. Zane
Independent Director
Independent Director
34.94K
--
Mr. David C. Habiger
Mr. David C. Habiger
Independent Director
Independent Director
3.55K
--
Mr. Yoshiaki Fujimori
Mr. Yoshiaki Fujimori
Independent Director
Independent Director
2.90K
--
Ms. Miriam O' Sullivan
Ms. Miriam O' Sullivan
Chief Human Resource Officer, Senior Vice President
Chief Human Resource Officer, Senior Vice President
--
--
Mr. Edward J. Ludwig
Mr. Edward J. Ludwig
Lead Independent Director
Lead Independent Director
--
--
Mr. Scott Olson
Mr. Scott Olson
Senior Vice President, President - Cardiac Rhythm Management and Diagnostics
Senior Vice President, President - Cardiac Rhythm Management and Diagnostics
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Michael F. (Mike) Mahoney
Mr. Michael F. (Mike) Mahoney
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
1.87M
-3.05%
Mr. Charles J. Dockendorff, CPA
Mr. Charles J. Dockendorff, CPA
Independent Director
Independent Director
62.90K
--
Mr. John E. Sununu
Mr. John E. Sununu
Independent Director
Independent Director
52.64K
--
Mr. Vance R. Brown
Mr. Vance R. Brown
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
36.19K
-11.77%
Ms. Ellen M. Zane
Ms. Ellen M. Zane
Independent Director
Independent Director
34.94K
--
Mr. David C. Habiger
Mr. David C. Habiger
Independent Director
Independent Director
3.55K
--
Revenue Breakdown
Currency: USDUpdate time: Sun, Apr 6
Currency: USDUpdate time: Sun, Apr 6
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Endoscopy
2.69B
16.04%
Interventional Cardiology Therapies
2.65B
15.79%
Peripheral Interventions
2.41B
14.39%
Cardiac Rhythm Management
2.28B
13.61%
Urology
2.20B
13.14%
Other
4.53B
27.03%
By RegionUSD
Name
Revenue
Proportion
United States
10.21B
60.97%
EMEA (Europe, Middle East and Africa)
3.23B
19.28%
Asia Pacific
2.69B
16.04%
Latin America and Canada
624.00M
3.73%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Endoscopy
2.69B
16.04%
Interventional Cardiology Therapies
2.65B
15.79%
Peripheral Interventions
2.41B
14.39%
Cardiac Rhythm Management
2.28B
13.61%
Urology
2.20B
13.14%
Other
4.53B
27.03%
Shareholder
Update time: Fri, Feb 21
Update time: Fri, Feb 21
Shareholder Statistics
Type
Shareholder Statistics
Shareholder
Proportion
The Vanguard Group, Inc.
8.94%
Fidelity Management & Research Company LLC
8.19%
BlackRock Institutional Trust Company, N.A.
5.19%
State Street Global Advisors (US)
4.32%
PRIMECAP Management Company
2.50%
Other
70.86%
Shareholder Statistics
Shareholder
Proportion
The Vanguard Group, Inc.
8.94%
Fidelity Management & Research Company LLC
8.19%
BlackRock Institutional Trust Company, N.A.
5.19%
State Street Global Advisors (US)
4.32%
PRIMECAP Management Company
2.50%
Other
70.86%
Type
Shareholder
Proportion
Investment Advisor
43.53%
Investment Advisor/Hedge Fund
37.31%
Hedge Fund
3.29%
Pension Fund
2.96%
Research Firm
2.47%
Bank and Trust
1.64%
Sovereign Wealth Fund
1.47%
Private Equity
0.21%
Insurance Company
0.21%
Other
6.91%
Institutional Shareholding
Update time: Sun, Jan 19
Update time: Sun, Jan 19
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q1
2544
1.38B
93.50%
+4.28M
2024Q4
2559
1.38B
93.61%
+1.09M
2024Q3
2417
1.37B
92.76%
-24.32M
2024Q2
2341
1.37B
93.29%
-18.17M
2024Q1
2227
1.37B
93.23%
-40.14M
2023Q4
2171
1.39B
94.95%
-25.34M
2023Q3
2110
1.39B
95.17%
-6.29M
2023Q2
2081
1.38B
95.67%
-15.63M
2023Q1
2012
1.36B
94.85%
-23.81M
2022Q4
1993
1.36B
94.66%
-54.91M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
132.25M
8.94%
+1.62M
+1.24%
Dec 31, 2024
Fidelity Management & Research Company LLC
121.20M
8.19%
-2.05M
-1.66%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
76.72M
5.19%
+7.50M
+10.84%
Dec 31, 2024
State Street Global Advisors (US)
63.96M
4.32%
+1.12M
+1.78%
Dec 31, 2024
PRIMECAP Management Company
36.93M
2.5%
-896.83K
-2.37%
Dec 31, 2024
Wellington Management Company, LLP
36.17M
2.45%
+3.34M
+10.19%
Dec 31, 2024
Geode Capital Management, L.L.C.
30.63M
2.07%
+1.04M
+3.52%
Dec 31, 2024
Capital World Investors
27.90M
1.89%
+6.22M
+28.67%
Dec 31, 2024
The Bollard Group, LLC
20.73M
1.4%
-510.32K
-2.40%
Dec 31, 2024
BlackRock Investment Management (UK) Ltd.
20.37M
1.38%
+757.90K
+3.86%
Dec 31, 2024
View more
Related ETFs
Update time: Sun, Apr 6
Update time: Sun, Apr 6
Name
Proportion
iShares U.S. Medical Devices ETF
10.77%
Goldman Sachs Future Health Care Equity ETF
8.56%
iShares Health Innovation Active ETF
5.12%
NYLI Healthy Hearts ETF
4.83%
JPMorgan Healthcare Leaders ETF
4.25%
Global X Aging Population ETF
3.98%
Hennessy Stance ESG ETF
3.4%
FT Raymond James Multicap Growth Equity ETF
2.84%
Tema Cardiovascular and Metabolic ETF
2.83%
iShares US Thematic Rotation Active ETF
2.82%
View more
iShares U.S. Medical Devices ETF
Proportion10.77%
Goldman Sachs Future Health Care Equity ETF
Proportion8.56%
iShares Health Innovation Active ETF
Proportion5.12%
NYLI Healthy Hearts ETF
Proportion4.83%
JPMorgan Healthcare Leaders ETF
Proportion4.25%
Global X Aging Population ETF
Proportion3.98%
Hennessy Stance ESG ETF
Proportion3.4%
FT Raymond James Multicap Growth Equity ETF
Proportion2.84%
Tema Cardiovascular and Metabolic ETF
Proportion2.83%
iShares US Thematic Rotation Active ETF
Proportion2.82%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data